633 related articles for article (PubMed ID: 20813489)
1. Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study.
Piacentini E; Sánchez B; Arauzo V; Calbo E; Cuchi E; Nava JM
J Crit Care; 2011 Apr; 26(2):201-5. PubMed ID: 20813489
[TBL] [Abstract][Full Text] [Related]
2. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection.
Ingram PR; Inglis T; Moxon D; Speers D
Intensive Care Med; 2010 Mar; 36(3):528-32. PubMed ID: 20069274
[TBL] [Abstract][Full Text] [Related]
3. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis.
Pfister R; Kochanek M; Leygeber T; Brun-Buisson C; Cuquemelle E; Machado MB; Piacentini E; Hammond NE; Ingram PR; Michels G
Crit Care; 2014 Mar; 18(2):R44. PubMed ID: 24612487
[TBL] [Abstract][Full Text] [Related]
4. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia.
Ramírez P; Ferrer M; Martí V; Reyes S; Martínez R; Menéndez R; Ewig S; Torres A
Crit Care Med; 2011 Oct; 39(10):2211-7. PubMed ID: 21705887
[TBL] [Abstract][Full Text] [Related]
6. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis.
Hoshina T; Nanishi E; Kanno S; Nishio H; Kusuhara K; Hara T
J Infect Chemother; 2014 Oct; 20(10):616-20. PubMed ID: 25027057
[TBL] [Abstract][Full Text] [Related]
7. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
[TBL] [Abstract][Full Text] [Related]
8. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
9. Procalcitonin kinetics in Legionella pneumophila pneumonia.
de Jager CP; de Wit NC; Weers-Pothoff G; van der Poll T; Wever PC
Clin Microbiol Infect; 2009 Nov; 15(11):1020-5. PubMed ID: 19438643
[TBL] [Abstract][Full Text] [Related]
10. Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia.
Ahn S; Kim WY; Kim SH; Hong S; Lim CM; Koh Y; Lim KS; Kim W
Influenza Other Respir Viruses; 2011 Nov; 5(6):398-403. PubMed ID: 21668682
[TBL] [Abstract][Full Text] [Related]
11. Procalcitonin in children admitted to hospital with community acquired pneumonia.
Moulin F; Raymond J; Lorrot M; Marc E; Coste J; Iniguez JL; Kalifa G; Bohuon C; Gendrel D
Arch Dis Child; 2001 Apr; 84(4):332-6. PubMed ID: 11259234
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit.
Boussekey N; Leroy O; Georges H; Devos P; d'Escrivan T; Guery B
Infection; 2005 Aug; 33(4):257-63. PubMed ID: 16091896
[TBL] [Abstract][Full Text] [Related]
13. [Procalcitonin in pyelonephritis and acute community-acquired pneumonia in adults].
Martinot M; Hansmann Y; De Martino S; Lesens O; Coumaros G; Pencreach E; Bertrand M; Christmann D
Presse Med; 2001 Jun; 30(22):1091-6. PubMed ID: 11484399
[TBL] [Abstract][Full Text] [Related]
14. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children.
Toikka P; Irjala K; Juvén T; Virkki R; Mertsola J; Leinonen M; Ruuskanen O
Pediatr Infect Dis J; 2000 Jul; 19(7):598-602. PubMed ID: 10917215
[TBL] [Abstract][Full Text] [Related]
15. Utility of serum procalcitonin and C-reactive protein in severity assessment of community-acquired pneumonia in children.
Agnello L; Bellia C; Di Gangi M; Lo Sasso B; Calvaruso L; Bivona G; Scazzone C; Dones P; Ciaccio M
Clin Biochem; 2016 Jan; 49(1-2):47-50. PubMed ID: 26386341
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical features and outcomes of hospitalized adult patients with novel influenza A (H1N1) pneumonia and other pneumonia.
Sohn CH; Ryoo SM; Yoon JY; Seo DW; Lim KS; Kim SH; Hong SB; Lim CM; Koh YS; Kim WY
Acad Emerg Med; 2013 Jan; 20(1):46-53. PubMed ID: 23570478
[TBL] [Abstract][Full Text] [Related]
17. The behavior and diagnostic utility of procalcitonin and five other inflammatory molecules in critically ill patients with respiratory distress and suspected 2009 influenza a H1N1 infection.
Paiva MB; Botoni FA; Teixeira AL; Miranda AS; Oliveira CR; Abrahão Jde O; Faria GM; Nobre V
Clinics (Sao Paulo); 2012; 67(4):327-34. PubMed ID: 22522757
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
Masiá M; Gutiérrez F; Shum C; Padilla S; Navarro JC; Flores E; Hernández I
Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
[TBL] [Abstract][Full Text] [Related]
19. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis.
Rodríguez AH; Avilés-Jurado FX; Díaz E; Schuetz P; Trefler SI; Solé-Violán J; Cordero L; Vidaur L; Estella Á; Pozo Laderas JC; Socias L; Vergara JC; Zaragoza R; Bonastre J; Guerrero JE; Suberviola B; Cilloniz C; Restrepo MI; Martín-Loeches I;
J Infect; 2016 Feb; 72(2):143-51. PubMed ID: 26702737
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
